2018–2020 Kivu Ebola epidemic

2018–2020 Kivu Ebola epidemic
Gregor Rom · CC BY-SA 3.0 · source
Name	2018–2020 Kivu Ebola epidemic
Caption	Map of affected provinces in the Democratic Republic of the Congo
Disease	Ebola virus disease
Virus strain	Zaire ebolavirus
Location	North Kivu, Ituri, Democratic Republic of the Congo
Dates	1 August 2018 – 25 June 2020
Confirmed cases	3,470
Deaths	2,287

2018–2020 Kivu Ebola epidemic The 2018–2020 Kivu Ebola epidemic was a major outbreak of Ebola virus disease in the provinces of North Kivu and Ituri in the Democratic Republic of the Congo. It overlapped with regional crises including armed conflict and humanitarian emergencies involving actors such as the Allied Democratic Forces, M23 rebellion remnants, and the Congolese army. International agencies including the World Health Organization, Médecins Sans Frontières, and the Centers for Disease Control and Prevention coordinated with the Government of the Democratic Republic of the Congo and local health authorities.

Background

The outbreak began in eastern Democratic Republic of the Congo amid ongoing instability in North Kivu and Ituri province. The region has a history of clashes involving local militias, the Union for the Congolese Nation, and transnational insurgents such as the Allied Democratic Forces. Prior Ebola outbreaks in the DRC, including the 2014 Équateur province Ebola outbreak and earlier episodes in Kikwit, informed preparedness but were challenged by the area's complex humanitarian context, displacement linked to the Kivu conflict, and weak infrastructure in cities like Goma and Beni.

Timeline

The index cluster was identified in late July 2018 in Mabalako and Mangina health zones, with the Ministry of Health announcing an outbreak in August 2018. Cases spread to urban centers including Goma in July 2019, prompting national and international alerts from the World Health Organization and the United Nations. The outbreak persisted through repeated waves with flare-ups in 2019 and 2020, culminating in a decline in cases and declaration of the end of the outbreak in June 2020 by WHO leadership after enhanced surveillance in North Kivu and Ituri province.

Response and containment

Response involved multiagency coordination among the World Health Organization, Médecins Sans Frontières, the Red Cross, the Centers for Disease Control and Prevention, the MONUSCO, and the European Union. Interventions included ring vaccination using the rVSV-ZEBOV vaccine, therapeutic trials such as the PALM trial testing monoclonal antibodies including REGN-EB3 and mAb114, laboratory support from the Institut National de Recherche Biomédicale, and community engagement with local leaders from Walikale and Butembo. Logistics relied on airports like Goma International Airport and coordination with agencies like UNICEF and World Food Programme to support surveillance, contact tracing, safe burials, and infection prevention and control in health facilities across contested territories.

Impact

The epidemic resulted in thousands of cases and deaths, strained health systems in North Kivu and Ituri province, and disrupted responses to endemic diseases such as measles and malaria. Humanitarian operations by Médecins Sans Frontières, International Rescue Committee, and the International Committee of the Red Cross faced access constraints due to attacks on health workers in towns including Beni and Butembo. Political repercussions influenced presidencies in Kinshasa and engagement by international actors including United States Department of State and the European Commission. The outbreak heightened attention to global health security doctrines such as the International Health Regulations and investments by entities like the Bill & Melinda Gates Foundation.

Virology and clinical features

The causative agent was Zaire ebolavirus, a filovirus related to pathogens studied in laboratories like the Centers for Disease Control and Prevention and the Institut Pasteur. Clinical presentation included fever, hemorrhage, gastrointestinal symptoms, and multi-organ failure observed in tertiary hospitals in Goma and referral centers such as Kikwit General Hospital. Diagnostic confirmation used polymerase chain reaction assays performed by regional reference labs supported by the WHO Global Outbreak Alert and Response Network. Therapeutics evaluated during the outbreak included REGN-EB3, mAb114, remdesivir, and supportive care protocols refined from prior experiences such as the 2014–2016 West Africa Ebola epidemic.

Controversies and challenges

Responses were complicated by armed group attacks, distrust of responders, and misinformation propagated via networks linked to urban centers like Goma and rural zones like Mambasa. Security incidents involving MONUSCO escorts and assaults on treatment centers raised questions for actors such as the United Nations and the African Union about protection of health workers. Vaccine deployment confronted ethical debates involving emergency use policies similar to discussions after the 2014–2016 West Africa Ebola epidemic, while clinical trial conduct prompted scrutiny by ethics boards connected to the National Institutes of Health and the London School of Hygiene & Tropical Medicine. Coordination among international and local institutions, including tensions between Kinshasa authorities and field teams from World Health Organization country offices, further complicated containment efforts.

Category:Ebola outbreaks Category:2018 in the Democratic Republic of the Congo Category:2019 in the Democratic Republic of the Congo Category:2020 in the Democratic Republic of the Congo